Transpek Industry Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Revenue fell ~29% in FY24, driven mostly by volume: Volume de-grew close to 25% as customers across polymer and other end industries cut off-take and avoided inventory, while price softened alongside raw material normalization.
• Recovery is expected to be gradual and back-half loaded: Management sees only a modest revival starting in H2 FY25, recovering 30%-40% of lost volumes, with the balance spilling into FY26.
• New products are the growth engine, but timing is uncertain: 3-4 non-acid chlorides are near final validation, and new acid chlorides contributed INR25-30 crores in FY24, yet customer testing cycles make launch dates impossible to pin down.
• Capital discipline stands out in a downcycle: The company walked away from a INR120+ crore Vizag capex when customer plans stalled, and now favors modifying existing facilities over greenfield, keeping the balance sheet clean.
• What to watch next quarter: Whether customer validations convert to commercial orders, any sign of volume recovery in the polymer division, and progress on the long-pending NSE listing application.

Revenue Decline: Volume, Price and Customer Behavior

• Volume was the dominant driver: Volume fell close to 25% in FY24, accounting for the majority of the ~29% revenue de-growth, with price reduction contributing the rest as raw material costs normalized from FY23 spikes.
• Polymer division led the drop: Sales in the polymer segment de-grew ~21%, predominantly from lower customer off-take rather than market share loss.
• Export market share held, domestic slipped slightly: In export markets, the volume decline was entirely demand-driven with no market share loss; in the smaller domestic market, there was some market share loss to a very small extent.
• Customers are ordering hand-to-mouth: Post-COVID, companies across the value chain are avoiding inventory build-up and placing back-to-back orders, a cautious approach driven by uncertainty rather than any structural market shift.
• Freight costs rose but were partly passed through: The Red Sea crisis increased freight and logistics costs in H2 and extended lead times as shipments took alternate routes, but a large part of freight cost is borne by customers.

Bimal Mehta: "overall market structure is not significantly changed. It is purely the cautious approach that everybody is taking because of the significant uncertainty and so nobody is ready to build inventories, nobody is ready to have significant quantities in the value chain."

New Products: The Pipeline and the Validation Bottleneck

• Acid chlorides already contributing: Over the last 3-4 years, 5-6 new acid chlorides were introduced; in FY24, these new products contributed about INR25-30 crores, without which revenue would have been INR570-575 crores.
• Non-acid chlorides are the next leg: 3-4 non-acid chloride products are on the verge of final validation, with customers currently conducting sample testing, shelf-life testing, and end-product performance testing before commercial supply can ramp up.
• Revenue potential is material but distant: These 3-4 non-acid chlorides have potential of around INR80-100 crores over the next 2-3 years; longer term, new products may reach INR150-170 crores. Management expects INR70-80 crores annually from new products starting FY26.
• Commercialization takes 2.5-3 years per product: Products go into critical applications (pharma, defense, fire-fighting, aircraft manufacturing), so validation cycles are long and gated by customer priorities, not just technical clearance.
• New geographies and applications opening: The company recently started business with customers in Eurasia and South America, began supplying to US customers, and started shipping acid chlorides it never previously supplied to the Korean market, with individual potentials of 1,000-4,000 metric tons per year.

Bimal Mehta: "Very difficult to say. I mean, like maybe three months, six months, eight months. It's very difficult to say like that because as I mentioned earlier, customer will do not only validation, customer will also do performance trial. Then first performance trial then second performance trial then commercial performance trial. So it's a process and sometimes these products are priority at customers and sometimes they are not."

Margin Profile: Quarterly Noise, Annual Consistency

• Quarterly margins swing on product mix: Q3 and Q4 had very similar revenues but very different margins because the company sells a diverse range of products into polymers, pharmaceuticals, different customers and regions; the same product to Region A vs Region B can carry different prices and margins, and demand for higher-margin vs lower-margin products varies quarter to quarter.
• Annual EBITDA has held a 17-20% band: Over the last four or five years, annual EBITDA has remained around 17% to 20%, so margins are quite consistent on an annual basis despite quarterly variation.
• Thionyl chloride is now fully captive: The company is consuming its entire thionyl chloride production internally and no longer sells to the dyes and pigments market, which remains in trouble and has not recovered.

Bimal Mehta: "So on an average, if you look at last four or five years' annual numbers, you will always find that we have remained around 17% to 20% EBITDA. So that way, margins are quite consistent. Quarter-to-Quarter you will definitely see variation."

Capital Allocation: Prudence Over Ambition

• Vizag capex was cancelled when customer plans stalled: The planned INR120+ crore Vizag investment was tied to specific customers whose growth plans halted due to COVID, war and other disruptions; Transpek aligned with those customers to wait, a decision management now calls prudent given how many chemical companies got into trouble with large investments and idle capacities.
• Greenfield is off the table for now: Management is taking a more prudent approach, with greenfield not very high on consideration; the preference is to modify an existing facility or take over a small facility with lower investment and less risk, and only when customer demand visibility and validation progress justify it.
• Buyback request met with a trade-off: When an analyst suggested a buyback given the strong balance sheet, management noted the conflict with investing in new facilities and said the board will decide what is right for the business.
• Silox investment is valuable but illiquid: Transpek retained a small shareholding in Silox India Private Limited after selling its sulphoxination division to Prayon Group in 2000; the stake has grown in value and pays very good dividends, but is privately held and not easy to encash.

Bimal Mehta: "we have taken a little more prudent approach... greenfield may be not very, very high on our consideration. It is under consideration, but not very high on our consideration."

End-Market Demand: Aramid, Pharma and the Dye Exit

• Aramid fibre market is subdued but structurally growing: Supply goes to high-end aramid fibres, where companies in Korea and Japan are expanding capacity (some almost doubling); no significantly competitive substitute material has emerged, and while growth is not exponential, it will continue. Chinese companies are active only in low-end aramid.
• Pharma chemical markets in new geographies are a target: The company has identified potential from the pharma chemical market in Africa, the Middle East, South America and Eurasia, with an objective to expand its range of value-added, high-margin products.
• Dye market remains in trouble: The dyes and pigments segment, which previously consumed thionyl chloride, has still not recovered, and Transpek has exited that market entirely by consuming all thionyl chloride captively.
• Long-term contracts are fading: The company is in dialogue with a couple of customers, and some big companies still favor long-term contracts, but generally nobody is keen to commit long-term due to uncertainty; management does not expect the same level or type of contracts as earlier, though they will provide stable, consistent business.

Bimal Mehta: "But what I feel is that maybe in another one, one and a half years' time, we should be seeing kind of back to glory days in chemical industry. This is my feeling. Now, it will also depend on how government policies and everything else is also because in my view, we have not been able to capture China plus one opportunities as much as we should have captured."

Guidance & Commitments

Key Metrics